AU636145B2 - New human parvovirus peptides with disulfide bridge for immunization or diagnosis - Google Patents
New human parvovirus peptides with disulfide bridge for immunization or diagnosis Download PDFInfo
- Publication number
- AU636145B2 AU636145B2 AU55596/90A AU5559690A AU636145B2 AU 636145 B2 AU636145 B2 AU 636145B2 AU 55596/90 A AU55596/90 A AU 55596/90A AU 5559690 A AU5559690 A AU 5559690A AU 636145 B2 AU636145 B2 AU 636145B2
- Authority
- AU
- Australia
- Prior art keywords
- cys
- ser
- lys
- document
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 53
- 241000484121 Human parvovirus Species 0.000 title claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 16
- 230000003053 immunization Effects 0.000 title claims description 9
- 238000003745 diagnosis Methods 0.000 title description 5
- 238000002649 immunization Methods 0.000 title description 3
- 239000000427 antigen Substances 0.000 claims description 42
- 102000036639 antigens Human genes 0.000 claims description 42
- 108091007433 antigens Proteins 0.000 claims description 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 17
- 238000002965 ELISA Methods 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 13
- 238000003018 immunoassay Methods 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 9
- 239000010839 body fluid Substances 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 241000125945 Protoparvovirus Species 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 108700016947 Bos taurus structural-GP Proteins 0.000 claims 1
- 101100095796 Caenorhabditis elegans sig-7 gene Proteins 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 238000012512 characterization method Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims 1
- 108010087823 glycyltyrosine Proteins 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 238000013507 mapping Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- CCTIOCVIZPCTGO-BYPYZUCNSA-N phosphoarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NP(O)(O)=O CCTIOCVIZPCTGO-BYPYZUCNSA-N 0.000 claims 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000005864 Sulphur Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000702617 Human parvovirus B19 Species 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BGGHCRNCRWQABU-JTQLQIEISA-N (2s)-2-amino-5-oxo-5-phenylmethoxypentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)OCC1=CC=CC=C1 BGGHCRNCRWQABU-JTQLQIEISA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000007985 Erythema Infectiosum Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 208000006031 Hydrops Fetalis Diseases 0.000 description 1
- 206010020529 Hydrops foetalis Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 231100001046 intrauterine death Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- ZERULLAPCVRMCO-UHFFFAOYSA-N sulfure de di n-propyle Natural products CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14211—Erythrovirus, e.g. B19 virus
- C12N2750/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8901566 | 1989-04-28 | ||
| SE8901566A SE8901566D0 (sv) | 1989-04-28 | 1989-04-28 | Nya peptider inkluderande en disulfidbindning |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5559690A AU5559690A (en) | 1990-11-29 |
| AU636145B2 true AU636145B2 (en) | 1993-04-22 |
Family
ID=20375840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU55596/90A Expired - Fee Related AU636145B2 (en) | 1989-04-28 | 1990-04-25 | New human parvovirus peptides with disulfide bridge for immunization or diagnosis |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0470205A1 (de) |
| AU (1) | AU636145B2 (de) |
| CA (1) | CA2053240A1 (de) |
| IL (1) | IL94218A0 (de) |
| SE (1) | SE8901566D0 (de) |
| WO (1) | WO1990013567A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274307B1 (en) * | 1990-02-08 | 2001-08-14 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | Immunologically active peptides or polypeptides from the parvovirus B19 |
| US5244785A (en) * | 1991-02-01 | 1993-09-14 | Microgenics Corporation | Determination of high molecular weight analytes using a β-galactosidase complementation assay |
| JPH0910000A (ja) | 1995-06-26 | 1997-01-14 | Nippon Sekijiyuujishiya | ヒトパルボウイルスの検出方法及びそのための試薬 |
| US6238860B1 (en) | 1998-11-05 | 2001-05-29 | Dyax Corp. | Binding moieties for human parvovirus B19 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0117063A1 (de) * | 1983-01-19 | 1984-08-29 | Amgen | Methoden und Materialien zur Entwicklung von Parvovirus-Vakzin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3782350D1 (de) * | 1986-03-20 | 1992-12-03 | Abbott Lab | Rekombinante parvovirus-ra-1-produkte und verfahren zu deren anwendung. |
-
1989
- 1989-04-28 SE SE8901566A patent/SE8901566D0/xx unknown
-
1990
- 1990-04-25 EP EP90908131A patent/EP0470205A1/de not_active Withdrawn
- 1990-04-25 CA CA002053240A patent/CA2053240A1/en not_active Abandoned
- 1990-04-25 WO PCT/SE1990/000276 patent/WO1990013567A1/en not_active Application Discontinuation
- 1990-04-25 AU AU55596/90A patent/AU636145B2/en not_active Expired - Fee Related
- 1990-04-26 IL IL94218A patent/IL94218A0/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0117063A1 (de) * | 1983-01-19 | 1984-08-29 | Amgen | Methoden und Materialien zur Entwicklung von Parvovirus-Vakzin |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1990013567A1 (en) | 1990-11-15 |
| AU5559690A (en) | 1990-11-29 |
| EP0470205A1 (de) | 1992-02-12 |
| SE8901566D0 (sv) | 1989-04-28 |
| IL94218A0 (en) | 1991-01-31 |
| CA2053240A1 (en) | 1990-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5981170A (en) | Peptides, artificial antigens and immunoassay kits | |
| DE3876496T2 (de) | Synthetisches peptid-antigen fuer nachweis von hiv-2-infektionen. | |
| JP2675009B2 (ja) | 改良ペプチド組成物およびｈｉｖに対する抗体の検出方法 | |
| RU1802871C (ru) | Способ определени антител к Н @ V - 1 | |
| WO1989008664A1 (en) | Synthetic peptide antigens for the detection of htlv-1 infection | |
| DE3854550T2 (de) | HIV-Peptide und Methoden für den Nachweis von HIV. | |
| Zhang et al. | Detection of rubella virus-specific immunoglobulin G (IgG), IgM, and IgA antibodies by immunoblot assays | |
| JP3533214B2 (ja) | Ｈｉｖ抗体検出用の合成ペプチドとその混合物 | |
| JP2650217B2 (ja) | Ｈｔｌｖ―１感染の診断、治療及び予防接種のためのペプチド | |
| DE3887053T4 (de) | Stlv-iii-verwandte polypeptide, diagnosesysteme und testmethoden. | |
| Mauracher et al. | Selective tolerance to the E1 protein of rubella virus in congenital rubella syndrome. | |
| AU636145B2 (en) | New human parvovirus peptides with disulfide bridge for immunization or diagnosis | |
| DE3850593T3 (de) | Synthetische Antigene zur Bestimmung der AIDS-bezogenen, von LAV-2 verursachten Krankheiten. | |
| US5068174A (en) | T-cell lymphotrophic virus protein and assay | |
| Mathiesen et al. | Analysis of a subclass-restricted HIV-1 gp41 epitope by omission peptides. | |
| DE69837666T2 (de) | Synthetische antigene zum nachweis von antikörpern mit immunreaktivität gegen hiv-virus | |
| JP2837669B2 (ja) | Ｔ−細胞リンパ趨行性ウイルス蛋白及びその分析 | |
| RU2184742C2 (ru) | Синтетические пептиды, применяемые в биологических тестах для обнаружения инфекций, вызванных вирусами вич-1 группы 0 | |
| AU756368B2 (en) | Peptide structures and their use in diagnosis of herpes simplex virus type 2 | |
| EP0677117A4 (de) | ||
| AU627701B2 (en) | Hiv peptides, artificial hiv antigens and immunoassay kits | |
| JP2002511853A (ja) | Ｈｉｖ抗体の検出方法及びそれに使用する抗原 | |
| JPH06293798A (ja) | ヒトパルボウイルスｂ１９のエピトープ関連ペプチド | |
| JP2010248194A (ja) | ペプチド構造物およびそれらの単純ヘルペスウイルス２型の診断における使用 | |
| JP2007224043A (ja) | ペプチド構造物およびそれらの単純ヘルペスウイルス２型の診断における使用 |